Biclonality in hairy cell leukemia: Co‐occurrence of <scp>CD10</scp><sup>+</sup> and <scp>CD10</scp><sup>−</sup> clones with different surface membrane immunoglobulin expression

Gorrese, Marisa; Guariglia, Roberto; Campana, Annapaola; Bertolini, A.; Fresolone, Lucia; Martorelli, Maria Carmen; Serio, Bianca; Selleri, Carmine; Giudice, Valentina

doi:10.1002/cyto.b.22096

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCL-v is often characterized by lower expression of CD25 and CD123 ( 353 ). Furthermore, there are reports of CD10 +/- biclonality ( 354 ), CD103 - cells ( 355 ), variable expression of CD123 on HCL-v cells ( 356 ), or cases with expression of both CD38 and CD10 ( 357 ).…”

Section: Hairy Cell Leukemiamentioning

confidence: 99%

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Karsten,

Matrisch,

Cichutek

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Engineering immune cells to treat hematological malignancies has been a major focus of research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several diseases can now be treated in highly therapy-refractory or relapsed conditions. Currently, a number of CD19- or BCMA-specific CAR-T-cell therapies are approved for acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma (MM), and follicular lymphoma (FL). The implementation of these therapies has significantly improved patient outcome and survival even in cases with previously very poor prognosis. In this comprehensive review, we present the current state of research, recent innovations, and the applications of CAR-T-cell therapy in a selected group of hematologic malignancies. We focus on B- and T-cell malignancies, including the entities of cutaneous and peripheral T-cell lymphoma (T-ALL, PTCL, CTCL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), classical Hodgkin-Lymphoma (HL), Burkitt-Lymphoma (BL), hairy cell leukemia (HCL), and Waldenström’s macroglobulinemia (WM). While these diseases are highly heterogenous, we highlight several similarly used approaches (combination with established therapeutics, target depletion on healthy cells), targets used in multiple diseases (CD30, CD38, TRBC1/2), and unique features that require individualized approaches. Furthermore, we focus on current limitations of CAR-T-cell therapy in individual diseases and entities such as immunocompromising tumor microenvironment (TME), risk of on-target-off-tumor effects, and differences in the occurrence of adverse events. Finally, we present an outlook into novel innovations in CAR-T-cell engineering like the use of artificial intelligence and the future role of CAR-T cells in therapy regimens in everyday clinical practice.

show abstract

Section: Hairy Cell Leukemiamentioning

confidence: 99%

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Karsten,

Matrisch,

Cichutek

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A

Novellis

Giudice

Ciccone

et al. 2022

JCM

View full text Add to dashboard Cite

Hairy cell leukemia (HCL) treatment in elderly, frail subjects is still unsatisfactory, and interferons, old-fashioned therapies, can be effectively used in this subset of patients. Here, to the best of our knowledge, we report for the first time an old, frail HCL patient effectively and safely treated with pegylated interferon-α-2a in monotherapy as a first-line treatment. At diagnosis, the patient arrived in a life-threating condition due to severe neutropenia and splenomegaly with high risk of splenic rupture. However, splenectomy was proposed and refused by the patient; therefore, a therapy with pegylated interferon-α-2a was initiated. After six months of therapy, the patient displayed the disappearance of palpable splenomegaly and of peripheral hairy cells at morphological examination without any drug-related adverse event. Our case report supports the use of pegylated interferon-α-2a in monotherapy as an effective and safe alternative therapeutic option in frail, elderly patients not eligible for purine analogous or targeted therapies.

show abstract

Biclonality in hairy cell leukemia: Co‐occurrence of CD10⁺ and CD10⁻ clones with different surface membrane immunoglobulin expression

Cited by 2 publications

References 2 publications

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Broadening the horizon: potential applications of CAR-T cells beyond current indications

A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A

Contact Info

Product

Resources

About

Biclonality in hairy cell leukemia: Co‐occurrence of CD10+ and CD10− clones with different surface membrane immunoglobulin expression

Cited by 2 publications

References 2 publications

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Broadening the horizon: potential applications of CAR-T cells beyond current indications

A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A

Contact Info

Product

Resources

About

Biclonality in hairy cell leukemia: Co‐occurrence of CD10⁺ and CD10⁻ clones with different surface membrane immunoglobulin expression